43769 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 14
15:22 UTC
|
PTCT
PTC Therapeutics
|
◎ Target | Eliana Merle ★★★☆☆ #1396 | Overweight | $120.00→ $122.00+1.7% |
|
Aug 14
15:22 UTC
|
PD
PagerDuty
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Sec→ r Perform | $9.00→ $12.00+33.3% |
|
Aug 14
15:22 UTC
|
PATH
UiPath
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Sec→ r Perform | $12.00→ $15.00+25.0% |
|
Aug 14
15:22 UTC
|
OKTA
Okta
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Outperform | $145.00→ $166.00+14.5% |
|
Aug 14
15:22 UTC
|
NU
NU
|
◎ Target | James Friedman ★★★☆☆ #1278 | Neutral | $13.00→ $16.00+23.1% |
|
Aug 14
15:22 UTC
|
NTSK
Netskope
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Outperform | $13.00→ $18.00+38.5% |
|
Aug 14
15:22 UTC
|
NTNX
Nutanix
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Outperform | $58.00→ $84.00+44.8% |
|
Aug 14
15:22 UTC
|
MSGS
Madison Square Garden
|
◎ Target | Joseph Stauff ★★★☆☆ #1985 | Positive | $430.00→ $477.00+10.9% |
|
Aug 14
15:22 UTC
|
MLAB
Mesa Laboratories
|
◎ Target | Evan Stampler not yet tracked | Equal Weight | $94.00→ $110.00+17.0% |
|
Aug 14
15:22 UTC
|
JPM
JPMorgan Chase & Co.
|
◎ Target | Mike Mayo ★★★★☆ #694 | Overweight | $375.00→ $390.00+4.0% |
|
Aug 14
15:22 UTC
|
IOT
Samsara
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Outperform | $42.00→ $50.00+19.0% |
|
Aug 14
15:22 UTC
|
IDN
Intellicheck
|
◎ Target | Rudy Kessinger ★★★★★ #155 | Buy | $7.50→ $5.00-33.3% |
|
Aug 14
15:22 UTC
|
HTFL
Heartflow
|
◎ Target | Larry Biegelsen ★★★★☆ #816 | Overweight | $37.00→ $39.00+5.4% |
|
Aug 14
15:22 UTC
|
GTLB
GitLab
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Sec→ r Perform | $29.00→ $46.00+58.6% |
|
Aug 14
15:22 UTC
|
GLOB
Globant
|
◎ Target | James Friedman ★★★☆☆ #1278 | Positive | $78.00→ $70.00-10.3% |
|
Aug 14
15:22 UTC
|
FATE
Fate Therapeutics
|
◎ Target | Yanan Zhu ★★☆☆☆ #2578 | Equal Weight | $2.50→ $3.50+40.0% |
|
Aug 14
15:22 UTC
|
EOSE
Eos Energy Enterprises
|
◎ Target | Ryan Pfingst ★☆☆☆☆ #3070 | Neutral | $8.00→ $5.00-37.5% |
|
Aug 14
15:22 UTC
|
DAN
Dana
|
◎ Target | Dan Levy ★★★☆☆ #1944 | Equal Weight | $33.00→ $35.00+6.1% |
|
Aug 14
15:22 UTC
|
CLBT
Cellebrite DI
|
◎ Target | Rudy Kessinger ★★★★★ #155 | Buy | $22.00→ $15.00-31.8% |
|
Aug 14
15:22 UTC
|
CABA
Cabaletta Bio
|
◎ Target | Derek Archila ★★☆☆☆ #2285 | Equal Weight | $4.00→ $3.00-25.0% |
|
Aug 14
15:22 UTC
|
BZAI
Blaize
|
◎ Target | Craig Ellis ★☆☆☆☆ #3130 | Buy | $4.00→ $2.00-50.0% |
|
Aug 14
15:22 UTC
|
ASND
Ascendis Pharma A/S
|
◎ Target | Eliana Merle ★★★☆☆ #1396 | Overweight | $345.00→ $329.00-4.6% |
|
Aug 14
15:22 UTC
|
AMGN
Amgen
|
◎ Target | Emily Field ★★★★☆ #837 | Equal Weight | $360.00→ $380.00+5.6% |
|
Aug 14
15:22 UTC
|
AMCR
Amcor
|
◎ Target | Gabe Hajde not yet tracked | Equal Weight | $43.00→ $44.00+2.3% |
|
Aug 14
15:22 UTC
|
AMAT
Applied Materials
|
◎ Target | Srini Pajjuri ★★☆☆☆ #2416 | Outperform | $520.00→ $600.00+15.4% |
|
Aug 14
15:22 UTC
|
ALNY
Alnylam Pharmaceuticals
|
◎ Target | Derek Archila ★★☆☆☆ #2285 | Equal Weight | $316.00→ $256.00-19.0% |
|
Aug 14
15:22 UTC
|
AHR
American Healthcare REIT
|
◎ Target | Michael Carroll ★★★★☆ #692 | Outperform | $56.00→ $61.00+8.9% |
|
Aug 14
15:22 UTC
|
ACM
AECOM
|
◎ Target | Andrew Wittmann ★★★★☆ #568 | Neutral | $73.00→ $65.00-11.0% |
|
Aug 14
14:22 UTC
|
MSGS
Madison Square Garden
|
◎ Target | Curry Baker ★★★☆☆ #1782 | Buy | $522.00→ $584.00+11.9% |
|
Aug 14
14:22 UTC
|
GLOB
Globant
|
◎ Target | Jonathan Lee not yet tracked | Buy | $55.00→ $50.00-9.1% |
|
Aug 14
14:22 UTC
|
ETON
Eton Pharmaceuticals
|
◎ Target | Swayampakula Ramakanth ★★☆☆☆ #2738 | Buy | $65.00→ $70.00+7.7% |
|
Aug 14
14:22 UTC
|
ESTC
Elastic
|
◎ Target | Matthew Hedberg ★★★★☆ #497 | Outperform | $70.00→ $87.00+24.3% |
|
Aug 14
14:22 UTC
|
EIKN
Eikon Therapeutics
|
◎ Target | Robert Driscoll ★★☆☆☆ #2402 | Underperform | $5.00→ $4.00-20.0% |
|
Aug 14
14:22 UTC
|
DE
Deere & Company
|
◎ Target | Tami Zakaria ★★★☆☆ #1063 | Neutral | $590.00→ $570.00-3.4% |
|
Aug 14
14:22 UTC
|
APPN
Appian
|
◎ Target | Lucky Schreiner ★★★★☆ #547 | Neutral | $34.00→ $42.00+23.5% |
|
Aug 14
14:22 UTC
|
AMAT
Applied Materials
|
◎ Target | Harlan Sur ★★☆☆☆ #2333 | Overweight | $515.00→ $660.00+28.2% |
|
Aug 14
14:22 UTC
|
ALH
Alliance Laundry
|
◎ Target | Tomohiko Sano ★★☆☆☆ #2652 | Overweight | $31.00→ $32.00+3.2% |
|
Aug 14
14:22 UTC
|
AIT
Applied Industrial Technologies
|
◎ Target | Chris Dankert ★★★☆☆ #1332 | Buy | $380.00→ $400.00+5.3% |
|
Aug 14
14:22 UTC
|
AEBI
Aebi Schmidt
|
◎ Target | Michael Shlisky ★★☆☆☆ #2837 | Buy | $15.00→ $17.00+13.3% |
|
Aug 14
14:22 UTC
|
ADEA
Adeia
|
◎ Target | Hamed Khorsand ★★☆☆☆ #2856 | Buy | $30.00→ $50.00+66.7% |
|
Aug 14
13:22 UTC
|
YETI
YETI
|
◎ Target | Jim Duffy not yet tracked | Hold | $42.00→ $45.00+7.1% |
|
Aug 14
13:22 UTC
|
YETI
YETI
|
◎ Target | Robert Ohmes ★★★☆☆ #1846 | Neutral | $44.00→ $48.00+9.1% |
|
Aug 14
13:22 UTC
|
WWW
Wolverine World Wide
|
◎ Target | Peter McGoldrick ★★★★☆ #889 | Buy | $25.00→ $26.00+4.0% |
|
Aug 14
13:22 UTC
|
WDAY
Workday
|
◎ Target | Brent Thill ★★★☆☆ #1704 | Hold | $140.00→ $205.00+46.4% |
|
Aug 14
13:22 UTC
|
WDAY
Workday
|
◎ Target | Karl Keirstead ★★★☆☆ #1079 | Neutral | $140.00→ $220.00+57.1% |
|
Aug 14
13:22 UTC
|
VERI
Veritone
|
◎ Target | Joshua Reilly ★★★☆☆ #1249 | Buy | $5.00 |
|
Aug 14
13:22 UTC
|
TRVI
Trevi Therapeutics
|
◎ Target | Debanjana Chatterjee ★★☆☆☆ #2872 | Buy | $24.00→ $28.00+16.7% |
|
Aug 14
13:22 UTC
|
TPR
Tapestry
|
◎ Target | Robert Drbul ★★★★☆ #814 | Buy | $180.00→ $175.00-2.8% |
|
Aug 14
13:22 UTC
|
TGT
Target
|
◎ Target | Corey Tarlowe ★★★★☆ #659 | Buy | $161.00→ $177.00+9.9% |
|
Aug 14
13:22 UTC
|
SGMT
Sagimet Biosciences
|
◎ Target | Jonathan Wolleben ★★☆☆☆ #2702 | Market Outperform | $12.00→ $29.00+141.7% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.